A combination of Sarclisa (isatuximab) plus standard Kyprolis (carfilzomib) and dexamethasone treatment significantly delays disease progression or death in people with relapsed or refractory multiple myeloma, interim results from a Phase 3 clinical trial suggest. The findings were shared at the European Hematology Association (EHA) 2020 Virtual Congress, in a presentation titled, “Isatuximab plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (IKEMA): interim analysis of a Phase 3, randomized, open-label study.” Sarclisa, developed…
You must be logged in to read/download the full post.
The post Sarclisa Triple Combo Prolongs Life Without Disease Progression in Some Myeloma Patients, Interim Data Show appeared first on BioNewsFeeds.